Incyte Corporation Reports 20% Revenue Growth to $1.366 Billion in Q3 2025

Incyte Corporation reported significant financial performance for the third quarter of 2025, with total revenues reaching $1.366 billion, a 20% increase from $1.138 billion in the same period last year. The company's product revenues, net of discounts and allowances, amounted to $1.150 billion, up from $963 million in the prior year, driven primarily by increased demand for its flagship product, JAKAFI (ruxolitinib), which generated $791 million in revenue, compared to $741 million in the previous year. The company also reported a net income of $424.2 million, translating to a basic net income per share of $2.17, a substantial rise from $106.5 million and $0.55 per share in Q3 2024.

In comparison to the previous fiscal period, Incyte's financials showed a marked recovery, particularly in net income, which surged from a loss of $168.6 million in the first nine months of 2024 to a profit of $987.4 million in the same period of 2025. This turnaround was attributed to improved operational efficiencies and a favorable settlement agreement with Novartis regarding royalty payments, which reduced future royalty obligations by 50%. The company also reported a significant decrease in accrued liabilities, from $1.213 billion at the end of 2024 to $948 million by September 30, 2025.

Strategically, Incyte has made notable advancements, including the acquisition of exclusive global rights to tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy, and the purchase of Escient Pharmaceuticals, which expanded its pipeline in immune and neuro-immune disorders. The company has also launched NIKTIMVO (axatilimab) and ZYNYZ (retifanlimab) in the U.S. market, contributing to its revenue growth. As of September 30, 2025, Incyte's employee headcount increased to 1,800, reflecting its expansion efforts.

Operationally, Incyte has seen increased engagement metrics, with JAKAFI and OPZELURA (ruxolitinib cream) driving significant revenue growth. The company reported that OPZELURA's revenues rose to $188 million in Q3 2025, up from $139 million in Q3 2024, fueled by higher patient demand and refills. The geographic expansion of its products has also been notable, with revenues from outside the U.S. contributing to overall growth. The company anticipates continued growth in its product adoption rates and market share, particularly in the oncology and dermatology sectors.

Looking ahead, Incyte remains optimistic about its future, projecting continued revenue growth driven by its expanding product portfolio and strategic partnerships. The company plans to leverage its strong cash position, with $2.9 billion in cash and marketable securities, to support ongoing research and development initiatives, potential acquisitions, and to navigate any market fluctuations. Incyte's management expressed confidence in sustaining profitability and enhancing shareholder value through its strategic focus on innovative therapeutics.